These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12422305)

  • 1. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
    Gamelin E; Gamelin L; Bossi L; Quasthoff S
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):21-33. PubMed ID: 12422305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of oxaliplatin-induced peripheral neuropathy.
    Saif MW; Reardon J
    Ther Clin Risk Manag; 2005 Dec; 1(4):249-58. PubMed ID: 18360567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Oxaliplatin neurotoxicity].
    Gamelin L; Boisdron-Celle M; Morel A; Gamelin E
    Bull Cancer; 2006 Feb; 93 Suppl 1():S17-22. PubMed ID: 16491518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
    J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.
    Grolleau F; Gamelin L; Boisdron-Celle M; Lapied B; Pelhate M; Gamelin E
    J Neurophysiol; 2001 May; 85(5):2293-7. PubMed ID: 11353042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
    Park SB; Lin CS; Kiernan MC
    J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-related neurotoxicity: how and why?
    Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
    Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
    Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.
    Taieb S; Trillet-Lenoir V; Rambaud L; Descos L; Freyer G
    Cancer; 2002 May; 94(9):2434-40. PubMed ID: 12015768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current.
    Sittl R; Lampert A; Huth T; Schuy ET; Link AS; Fleckenstein J; Alzheimer C; Grafe P; Carr RW
    Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6704-9. PubMed ID: 22493249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin-associated neuropathy: a review.
    Cersosimo RJ
    Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute oxaliplatin-induced peripheral nerve hyperexcitability.
    Wilson RH; Lehky T; Thomas RR; Quinn MG; Floeter MK; Grem JL
    J Clin Oncol; 2002 Apr; 20(7):1767-74. PubMed ID: 11919233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of Transient Receptor Potential Ankyrin 1 in Oxaliplatin-Induced Peripheral Neuropathy.
    Nakagawa T; Kaneko S
    Biol Pharm Bull; 2017; 40(7):947-953. PubMed ID: 28674258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
    Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
    Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation.
    Heide R; Bostock H; Ventzel L; Grafe P; Bergmans J; Fuglsang-Frederiksen A; Finnerup NB; Tankisi H
    Clin Neurophysiol; 2018 Mar; 129(3):694-706. PubMed ID: 29233604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    PLoS One; 2011 Apr; 6(4):e18469. PubMed ID: 21494615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety profile of oxaliplatin.
    Extra JM; Marty M; Brienza S; Misset JL
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):13-22. PubMed ID: 9609104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.
    Webster RG; Brain KL; Wilson RH; Grem JL; Vincent A
    Br J Pharmacol; 2005 Dec; 146(7):1027-39. PubMed ID: 16231011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin and axonal Na+ channel function in vivo.
    Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
    Clin Cancer Res; 2006 Aug; 12(15):4481-4. PubMed ID: 16899592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.